GlassScriptPhysician profile
Jesse D Dunn
NPI 1093168098
$3,458.59
in general payments reported to CMS, 2019-2025
34 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $547 · 2021: $836 · 2022: $882 · 2023: $564 · 2024: $247 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,080.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $499.43 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $422.97 | 2019-2024 | Repatha, Otezla, Prolia |
| Novo Nordisk INC | $377.08 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Daiichi Sankyo INC. | $259.63 | 2020-2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.63 | 2020-2023 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $192.60 | 2021-2025 | |
| Pfizer INC. | $188.30 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $169.40 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $158.71 | 2020-2024 | Breztri |
| Novartis Pharmaceuticals Corporation | $149.53 | 2020-2023 | |
| Otsuka America Pharmaceutical, INC. | $138.25 | 2021-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $114.90 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $78.37 | 2020-2025 | Eliquis |
| Astellas Pharma US INC | $73.42 | 2022-2024 | Myrbetriq, Veozah |
| Glaxosmithkline, LLC. | $50.56 | 2020-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $47.72 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $39.69 | 2025 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $36.07 | 2021-2022 | |
| Dexcom, INC. | $28.25 | 2021-2024 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $22.32 | 2019-2021 | |
| Amarin Pharma, INC. | $18.89 | 2019 | |
| Sanofi Pasteur INC. | $18.63 | 2021 | |
| Organon LLC | $18.33 | 2022 | |
| Soleno Therapeutics, INC. | $18.28 | 2025 | Vykat Xr |
| Axsome Therapeutics, INC. | $17.92 | 2023 | Sunosi |
| Eisai INC. | $17.84 | 2020 | |
| Xeris Pharmaceuticals, INC. | $17.78 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $16.99 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.47 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.45 | 2022 | |
| Supernus Pharmaceuticals, INC. | $11.81 | 2021 | |
| Genentech USA, INC. | $11.33 | 2021 | |
| Travere Therapeutics, INC. | $8.95 | 2022 | |
| Phathom Pharmaceuticals, INC. | $6.09 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.